Key clinical point: Men vs women with psoriatic arthritis (PsA) experienced significantly improved outcomes with methotrexate+etanercept combination therapy, whereas those with lower body mass index (BMI) experienced better outcomes with no indication of any pattern with treatment received.
Major finding: At week 24, a higher proportion of men vs women receiving methotrexate+etanercept achieved American College of Rheumatology 20% (ACR20; 71.5% vs. 58.3%; P = .0194) and minimal disease activity (MDA; 45.8% vs 25.2%; P = .0003), whereas a higher proportion of patients with a BMI of ≤30 vs >30 kg/m 2 in all treatment groups achieved MDA (all P < .05) and those in methotrexate+etanercept group achieved ACR20 ( P = .0241).
Study details: This was a post hoc analysis of the phase 3 SEAM-PsA trial including 851 methotrexate/biologics naive patients with early PsA who were randomly assigned to receive methotrexate+placebo, etanercept+placebo, or methotrexate+etanercept.
Disclosures: This study was funded by Immunex, a subsidiary of Amgen. Two authors declared being employees of and owned stocks in Amgen. The other authors reported ties with various sources, including Amgen.
Source: Mease PJ et al. Potential impact of sex and body mass index on response to therapy in psoriatic arthritis: Post-hoc analysis of results from the SEAM-PsA trial. J Rheumatol. 2022 (Apr 15). Doi: 10.3899/jrheum.211037